Vicore Pharma Holding Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Ahmed Mousa
Chief executive officer
SEK 6.3m
Total compensation
| CEO salary percentage | 23.5% |
| CEO tenure | 1.9yrs |
| CEO ownership | n/a |
| Management average tenure | 1.9yrs |
| Board average tenure | 1.6yrs |
Recent management updates
Recent updates
We're Not Very Worried About Vicore Pharma Holding's (STO:VICO) Cash Burn Rate
Sep 11
Vicore Pharma Holding (STO:VICO) Is In A Good Position To Deliver On Growth Plans
Feb 10We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully
Sep 21We Think Vicore Pharma Holding (STO:VICO) Needs To Drive Business Growth Carefully
May 25Calculating The Intrinsic Value Of Vicore Pharma Holding AB (publ) (STO:VICO)
Jan 10Is Vicore Pharma Holding (STO:VICO) In A Good Position To Invest In Growth?
Nov 13Here's Why We're Watching Vicore Pharma Holding's (STO:VICO) Cash Burn Situation
Jul 26Is Vicore Pharma Holding AB (publ) (STO:VICO) Worth kr17.6 Based On Its Intrinsic Value?
Mar 03What You Need To Know About Vicore Pharma Holding AB (publ)'s (STO:VICO) Investor Composition
Jan 11
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -SEK 196m |
| Jun 30 2024 | n/a | n/a | -SEK 200m |
| Mar 31 2024 | n/a | n/a | -SEK 213m |
| Dec 31 2023 | SEK 6m | SEK 1m | -SEK 311m |
Compensation vs Market: Ahmed's total compensation ($USD574.88K) is about average for companies of similar size in the Swedish market ($USD454.41K).
Compensation vs Earnings: Insufficient data to compare Ahmed's compensation with company performance.
CEO
Ahmed Mousa (39 yo)
1.9yrs
Tenure
SEK 6,339,074
Compensation
Mr. Ahmed S. Mousa, J. D., serves as Chief Executive Officer at Vicore Pharma Holding AB (publ) since 2023. He served as General Counsel at Pieris Pharmaceuticals, Inc., since October 2018 until September...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 1.9yrs | SEK 6.34m | no data | |
| Chief Financial Officer | 7.5yrs | no data | 0.0021% SEK 39.3k | |
| Vice President of Operations & Corporate Strategy | less than a year | no data | 0.0017% SEK 31.7k | |
| Chief Scientific Officer | 6.9yrs | no data | 0.10% SEK 1.9m | |
| Chief Administrative Officer | 15.9yrs | no data | 0.010% SEK 192.5k | |
| VP of Investor Relations | less than a year | no data | no data | |
| Head of Digital Therapeutics & Director of Digital Innovation | 3.6yrs | no data | no data | |
| Chief Engagement & Commercial Officer | 3.2yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Vice President of Business Development | less than a year | no data | no data | |
| VP & Head of CMC | less than a year | no data | no data |
1.9yrs
Average Tenure
58yo
Average Age
Experienced Management: VICO's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | no data | SEK 886.00k | 0.0027% SEK 50.3k | |
| Director | 1.6yrs | SEK 405.00k | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Chairman | 6.3yrs | SEK 450.00k | 0.0017% SEK 31.5k | |
| Director | 1.6yrs | SEK 405.00k | no data | |
| Independent Director | 4.6yrs | SEK 519.00k | 0.0021% SEK 39.3k |
1.6yrs
Average Tenure
63yo
Average Age
Experienced Board: VICO's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:09 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vicore Pharma Holding AB (publ) is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hanseung Yoo | Bryan Garnier & Co |
| Oscar Haffen Lamm | Bryan Garnier & Co |
| Patrik Ling | DNB Markets |